Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Radiation × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Oropharyngeal Neoplasms 6 Lung Neoplasms 6 Glioblastoma 6 Breast Neoplasms 6 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Mouth Neoplasms 3 Laryngeal Neoplasms 3 Glioma 3 Carcinoma 3 Astrocytoma 3 Vaginal Neoplasms 2 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma, Embryonal 2 Rhabdomyosarcoma 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Liposarcoma 2 Leiomyosarcoma 2 Hypopharyngeal Neoplasms 2 Histiocytoma, Malignant Fibrous 2 Gliosarcoma 2 Ependymoma 2 Burkitt Lymphoma 2 Adenocarcinoma of Lung 2

Interventions

pembrolizumab 2 durvalumab 2 Standard of Care 2 Paclitaxel 2 Oxaliplatin 2 Irinotecan 2 Chemoradiotherapy 2 Carboplatin 2 Capecitabine 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 talazoparib 1 sarilumab 1 relugolix 1 regorafenib 1 pexidartinib 1 pertuzumab 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 enzalutamide 1 dostarlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡